Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings review
Oncology Turnaround Drives 19% Revenue Surge, But Sequential Softness Needs Monitoring
Jazz Pharmaceuticals delivered a strong 19% YoY revenue increase to $1.07B in Q1 2026. The highlight of the quarter was a dramatic turnaround in the oncology portfolio: Zepzelca sales surged 60% YoY to $101M following its first-line label expansion, and recently launched Modeyso added $41.4M. Despite this YoY strength, total revenue declined sequentially from Q4 2025's $1.20B, driven by QoQ drops in Xywav and Epidiolex. Non-GAAP EPS came in robust at $6.34, aided by a $122.8M gain from a Priority Review Voucher sale. Management reaffirmed FY26 revenue guidance of $4.25-$4.50B, which implies a sharp deceleration to low-single-digit growth for the full year, likely pricing in expected generic erosion in the legacy sleep franchise.
🐂 Bull Case
Zepzelca and Modeyso are successfully replacing legacy revenue. Zepzelca's approval in 1LM ES-SCLC completely reversed its prior growth declines, making oncology a true growth engine again.
Despite looming generic Xyrem threats, Xywav continues to post strong YoY growth (+18%) with 425 net patient adds in Q1, proving the stickiness of its low-sodium differentiation.
🐻 Bear Case
Q1 total revenues fell ~11% vs Q4 2025. Both Xywav ($408M vs $465M) and Epidiolex ($250M vs $287M) posted notable sequential declines, raising questions about whether Q4 benefited from inventory stocking or if early generic disruption is taking hold.
Non-GAAP gross margins compressed to 91.6% from 92.2% YoY. Ironically, this is driven by the success of newer products, which carry higher royalty burdens compared to the wholly-owned legacy sleep portfolio.
⚖️ Verdict: 🟢
Bullish. The 19% YoY top-line growth and the definitive reversal of Zepzelca's negative trajectory prove Jazz's pipeline pivot is executing as planned, even if sequential seasonality looks messy.
Key Themes
Zepzelca Trajectory Reverses on Label Expansion
Zepzelca went from an 8% YoY decline in mid-2025 to a 60% YoY surge in 26Q1, reaching $101M. This Reversing trend completely validates the strategic importance of the October 2025 FDA approval for its use in combination with atezolizumab in the first-line maintenance setting for ES-SCLC.
Modeyso Sustains Launch Momentum
Launched in August 2025, Modeyso delivered $41.4M in Q1, an acceleration from $36.5M in Q4 2025. With roughly 500 patients treated since launch, it is establishing a highly reliable new revenue stream in the rare oncology space.
Zanidatamab Catalyst Approaching Fast
The FDA accepted the sBLA for zanidatamab (Ziihera) under the Real-Time Oncology Review program for 1L HER2+ GEA, granting Priority Review with a PDUFA date of August 25, 2026. Data from the HERIZON-GEA-01 trial showing additional benefit irrespective of PD-L1 status positions this as the company's next major pillar.
Second-Line Zepzelca Erosion
While the 1L expansion is booming, management explicitly cautioned that 'second line use [is expected] to decline throughout the year.' The risk is whether the decaying 2L base will eventually outpace the growth from the 1L maintenance setting.
Gross Margin Compression from Mix Shift
Non-GAAP Cost of Product Sales increased from $69.7M (7.8% of sales) to $90.0M (8.4% of sales) YoY. Management attributed this to higher royalty expenses on growing products and increased inventory provisions. As the mix shifts further toward partnered oncology assets (like Zepzelca and Zanidatamab) and away from the legacy sleep franchise, gross margins will likely face structural, albeit minor, pressure.
Macro: Tariffs and Supply Chain Constraints
The company's forward-looking statements heavily flag geopolitical tensions and military conflicts impacting supply. Management previously spent heavily in 2025 to build U.S. inventory to front-run potential tariff implementations. If these inventories are burned down without pricing relief, COGS will spike in late 2026/2027.
Other KPIs
Accelerating. Up 8% YoY from $159.7M. This increase represents active investment in the Modeyso ACTION trial and broad zanidatamab label-expansion studies, signaling confidence in the mid-stage pipeline.
Stable. The company continues to generate immense cash, ending the quarter with $2.9 billion in cash and investments. The quarter's cash profile was further bolstered by the sale of a Rare Pediatric Disease PRV, delivering $100M in net proceeds to Jazz.
Guidance
Decelerating. Reaffirmed guidance. At the midpoint ($4.375B), this implies ~2.5% YoY growth vs FY25's $4.267B. Given the 19% growth just posted in Q1, this guidance implies management expects a severe slowdown or outright revenue contraction in the back half of the year, directly correlating to the anticipated impact of Xyrem generic competition.
Reversing. Down drastically from the $1.81B (GAAP) spent in FY25. This normalization removes the heavy litigation settlement costs from 2025 and reflects intense operational discipline to protect the bottom line while top-line growth decelerates.
Stable to slightly Decelerating. Q1 printed at 91.6%, meaning management expects gross margins to step down further through the year as royalty-bearing oncology products make up a larger share of the revenue mix.
Key Questions
Xywav Sequential Drop Context
Xywav dropped from $465M in Q4 to $408M in Q1. How much of this is standard Q1 payer dynamic and copay reset vs. early step-edits forcing patients to generic high-sodium oxybates?
Epidiolex Inventory Normalization
Epidiolex also saw a sharp sequential drop. Can management quantify if Q4 was artificially inflated by an inventory bolus, and does Q1 represent the true underlying demand run-rate?
Zepzelca 2L vs 1L Dynamics
With the expected decline in second-line Zepzelca usage, at what point do you expect the 1L maintenance growth to fully saturate, and what is the net peak revenue expectation once both lines normalize?